Discovery of BAY 3389934 Hydrochloride: A Potent and Selective Small-Molecule Dual Factor IIa/Xa Inhibitor with Short Half-Life for the Acute Treatment of Sepsis-Induced Coagulopathy
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c00538 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Hartmut Beck und 20 weiteren Autor:innen. Beteiligte Einrichtung: Bayer AG, Pharmaceuticals, Research & Development, 42113 Wuppertal, Germany. Hauptthemen laut MEDLINE: Sepsis, Factor Xa Inhibitors, Blood Coagulation Disorders, Factor XIa. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Sepsis
Abstract (Originalsprache)
Sepsis-induced coagulopathy (SIC) is a severe and frequent complication of sepsis, which is associated with high mortality in patients. So far, attempts have failed to establish a global standard of care in this difficult-to-treat indication. Anticoagulation with a dual inhibitor of the coagulation factors IIa (FIIa, thrombin) and Xa (FXa) has the potential to improve the treatment of life-threatening acute coagulation disorders, such as SIC. Herein, we describe the discovery of BAY 3389934 hydrochloride (31), a potent and highly selective, direct dual FIIa/Xa inhibitor, with high solubility suited for i.v. application. This small molecule acts as a metabolically soft active pharmaceutical ingredient (API) due to a labile carboxylic ester group, which is responsible for the desired short pharmacokinetic and pharmacological half-life (t1/2), resulting in a high controllability of the pharmacological action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Bayer AG, Pharmaceuticals, Research & Development, 42113 Wuppertal, Germany.
- F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland.
- UCB BioSciences GmbH, 40789 Monheim, Germany.
- Sanofi, 45 Chemin de Météline, 04200 Sisteron, France.
ORCID-Profile: Hartmut Beck, Stefanie Mesch, Alexandros Vakalopoulos, Markus Follmann
Zitieren
APA
Beck, H., Mesch, S., Zimmermann, S., Vakalopoulos, A., Lehmann, L., Gericke, K. M., Süßmeier, F., Baerfacker, L., Hillisch, A., Meier, K., Tersteegen, A., Buchmüller, A., Gerdes, C., Dietze-Torres, J., Kersten, E., Partikel, K., Bröhl, A., Levilain, G., Heitmeier, S., …, & Follmann, M. (2025). Discovery of BAY 3389934 Hydrochloride: A Potent and Selective Small-Molecule Dual Factor IIa/Xa Inhibitor with Short Half-Life for the Acute Treatment of Sepsis-Induced Coagulopathy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c00538
Vancouver
Beck H, Mesch S, Zimmermann S, Vakalopoulos A, Lehmann L, Gericke KM, et al. Discovery of BAY 3389934 Hydrochloride: A Potent and Selective Small-Molecule Dual Factor IIa/Xa Inhibitor with Short Half-Life for the Acute Treatment of Sepsis-Induced Coagulopathy. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c00538
BibTeX
@article{Beck2025,
author = {Beck, Hartmut and Mesch, Stefanie and Zimmermann, Stefanie and Vakalopoulos, Alexandros and Lehmann, Lutz and Gericke, Kersten Matthias and Süßmeier, Frank and Baerfacker, Lars and Hillisch, Alexander and Meier, Katharina and Tersteegen, Adrian and Buchmüller, Anja and Gerdes, Christoph and Dietze-Torres, Julia and Kersten, Elisabeth and Partikel, Katrin and Bröhl, Andreas and Levilain, Guillaume and Heitmeier, Stefan and Pfaff, Nils and Follmann, Markus},
title = {Discovery of BAY 3389934 Hydrochloride: A Potent and Selective Small-Molecule Dual Factor IIa/Xa Inhibitor with Short Half-Life for the Acute Treatment of Sepsis-Induced Coagulopathy},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c00538}
}
EUVIMED